{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:07:15Z","timestamp":1783508835716,"version":"3.55.0"},"reference-count":55,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T00:00:00Z","timestamp":1560729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>ECHELON\u20101 study is a randomized open\u2010labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow\u2010up of 24.6\u00a0months, it has met its primary endpoint the reduction of modified progression\u2010free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in\u2010depth insight of pros and cons of this novel, promising but ultimately controversial regimen.<\/jats:p>","DOI":"10.1111\/ejh.13269","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T09:14:29Z","timestamp":1559726069000},"page":"145-151","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?"],"prefix":"10.1111","volume":"103","author":[{"given":"Vibor","family":"Milunovi\u0107","sequence":"first","affiliation":[{"name":"Division of Hematology Clinical Hospital Merkur Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Mi\u0161ura Jakobac","sequence":"additional","affiliation":[{"name":"Division of Hematology Clinical Hospital Merkur Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Kursar","sequence":"additional","affiliation":[{"name":"Division of Hematology Clinical Hospital Merkur Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Mandac Rogulj","sequence":"additional","affiliation":[{"name":"Division of Hematology Clinical Hospital Merkur Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6487-3623","authenticated-orcid":false,"given":"Slobodanka","family":"Ostoji\u0107 Koloni\u0107","sequence":"additional","affiliation":[{"name":"Division of Hematology Clinical Hospital Merkur Zagreb Croatia"},{"name":"School of Medicine University of Zagreb Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0705-5"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30696-4"},{"key":"e_1_2_7_7_1","volume-title":"HD21 for Advanced Stages","author":"University of Cologne","year":"2016"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1630"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12813"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15602"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30140-6"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61940-5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32134-7"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0139"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1802363"},{"key":"e_1_2_7_20_1","first-page":"1559","article-title":"Brentuximab vedotin for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Greer JP","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_7_21_1","first-page":"1559","article-title":"Brentuximab vedotin for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Crump M","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_7_22_1","first-page":"1560","article-title":"Brentuximab vedotin for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Canellos GP","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_7_23_1","first-page":"8","article-title":"Brentuximab vedotin plus chemotherapy in high risk advanced\u2010stage classical Hodgkin Lymphoma (cHL) patients: results of pre\u2010specified sub\u2010group analyses from the ECHELON\u20101 study","volume":"2","author":"Hutchings M","year":"2018","journal-title":"HemaSphere"},{"key":"e_1_2_7_24_1","unstructured":"Cancer Research UK.Hodgkin lymphoma incidence statistics.https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/hodgkin-lymphoma\/incidence#heading. Accessed March 21 2019."},{"key":"e_1_2_7_25_1","first-page":"535","article-title":"Frontline brentuximab vedotin plus chemotherapy exhibits superior modified progression\u2010free survival vs chemotherapy alone in patients with stage III or IV Hodgkin lymphoma: phase 3 ECHELON\u20101 study","volume":"2","author":"Gallamini A","year":"2018","journal-title":"HemaSphere"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1084285"},{"key":"e_1_2_7_27_1","first-page":"531","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma: impact of cycle 2 pet result on modified progression\u2010free survival","volume":"2","author":"Chen R","year":"2018","journal-title":"HemaSphere"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1426877"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7541"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7534"},{"key":"e_1_2_7_31_1","volume-title":"A Safety Study of Growth Factor Use in Treatment With Brentuximab Vedotin Plus Chemotherapy","author":"Seattle Genetics, Inc","year":"2016"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112907"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112178"},{"key":"e_1_2_7_34_1","first-page":"35","article-title":"Population Pharmacokinetic (POPPK) modeling and Exposure\u2010Response (ER) assessment of brentuximab vedotin efficacy and safety in patients with advanced classical Hodgkin lymphoma (cHL) from the phase 3 ECHELON\u20101 sTUDY","volume":"0137","author":"Suri A","year":"2018","journal-title":"HemaSphere"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.09.018"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf333"},{"key":"e_1_2_7_37_1","first-page":"35","article-title":"sCD30 and tarc do not correlate with pet\u2010based response assessment in patients (pts) with Stage III or IV classical Hodgkin lymphoma (cHL): phase 3 ECHELON\u20101 study of brentuximab vedotin plus chemotherapy vs chemotherapy alone","volume":"0159","author":"Sureda A","year":"2018","journal-title":"HemaSphere"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111893"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5648"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn284"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00122"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.021"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1542599"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4803"},{"key":"e_1_2_7_46_1","first-page":"CD007941","article-title":"Comparison of first\u2010line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz N","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-007-0022-2"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.05.006"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.316"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30784-8"},{"key":"e_1_2_7_51_1","unstructured":"Food and Drug Agency.ADCETRIS.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125388s097lbl.pdf. Accessed March 23 2019."},{"key":"e_1_2_7_52_1","unstructured":"European Medicines Agency.ADCETRIS Summary of Product Characteristics.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adcetris-epar-product-information_en.pdf. Accessed March 23 2019."},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-845438"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2016.08.011"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0013"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2435"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13269","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T18:40:03Z","timestamp":1692988803000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,17]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/ejh.13269"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13269","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,17]]},"assertion":[{"value":"2019-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}